JPMorgan raised the firm’s price target on Novo Nordisk to DKK 850 from DKK 800 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Eli Lilly’s (NYSE:LLY) Obesity Treatment Enters the U.S. Market
- Weight-loss drug developers rise after Roche agrees to buy Carmot
- Novo Nordisk price target raised to $115 from $105 at TD Cowen
- Elastic upgraded, Alibaba downgraded: Wall Street’s top analyst calls
- Novo Nordisk price target raised to $115 from $110 at Argus